Moderna (MRNA) Osake Kurssi

Moderna Inc is primarily active in the biotechnology and pharmaceutical industries.

Moderna Inc faces competition from various companies in the market, including established pharmaceutical giants such as Pfizer, Johnson & Johnson, and AstraZeneca. These competitors also focus on developing and distributing vaccines and therapeutics, much like Moderna Inc. However, Moderna Inc stands out for its pioneering messenger RNA (mRNA) technology, which has gained significant attention and recognition. With its innovative approach and potential for addressing unmet medical needs, Moderna Inc continues to position itself as a prominent player in the biopharmaceutical industry and compete against other industry leaders in the market.

Moderna Inc, a leading biotechnology company, was founded in 2010. Headquartered in Cambridge, Massachusetts, Moderna specializes in the development of mRNA-based medicines and therapies. By utilizing the potential of messenger RNA (mRNA) technology, the company aims to revolutionize the field of medicine. Moderna has a diverse pipeline of investigational programs, targeting various diseases, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. The company's commitment to innovation and cutting-edge research has attracted strategic collaborations with renowned organizations and industry leaders. With its groundbreaking approach and promising advancements, Moderna Inc continues to make significant contributions to the biomedical field.

Moderna Inc, a renowned biotechnology company, has achieved several significant milestones. Notably, Moderna became the first company to release an mRNA-based vaccine authorized for emergency use against COVID-19, known as the Moderna COVID-19 Vaccine. This breakthrough marked a monumental achievement in the fight against the global pandemic. Additionally, Moderna has made remarkable progress in advancing mRNA-based therapies for various diseases, including cancer and rare genetic disorders. Through strategic collaborations and cutting-edge research, Moderna has demonstrated its commitment to revolutionize medicine by harnessing the power of mRNA technology. Moderna Inc's dedication to innovation and groundbreaking achievements position it as a leading player in the biotech industry.

Moderna Inc is primarily present in several countries and regions worldwide. The company has its headquarters in Cambridge, Massachusetts, United States. Apart from the US, Moderna Inc has a notable presence in various countries and regions such as Europe, including the United Kingdom, Germany, France, and Switzerland. Additionally, Moderna Inc operates in Asia, with a presence in Japan and South Korea. The company also has collaborations and partnerships with organizations and institutions globally, enabling its presence in diverse regions for the development and distribution of its innovative mRNA-based vaccines and therapies.

Moderna Inc represents a commitment to pioneering transformative medicines based on messenger RNA (mRNA) technology. The company's corporate philosophy centers around innovation, collaboration, and patient-focused progress. Moderna believes in leveraging its proprietary mRNA platform to develop a vast range of potential therapeutics and vaccines to tackle various diseases. The company strives to address unmet medical needs and improve global healthcare through its cutting-edge research and development efforts. Moderna's dedication to scientific excellence, forward-thinking strategies, and ongoing partnerships positions it as a leader in the biotechnology industry, driving breakthroughs and shaping the future of medicine.

Analyytikot asettavat tällä hetkellä Moderna-osakkeelle keskimääräisen tavoitehinnan 70,73 USD (mediaani: 57,12 USD), mikä merkitsee −65,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 33 analyytikkoarvioon.

Moderna Analyytikkojen kursstavoitteet 2026

30 analyytikkoa arvioi tällä hetkellä Moderna-osaketta: 11 suosittaa ostoa, 17 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Moderna-yhtiöltä 2,10 Mrd. USD liikevaihtoa ja −8,29 USD osakekohtaista tulosta.

Moderna Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Moderna-osake noteerataan hintaan 172,24 EUR (195,39 USD).

Moderna-osake (MRNA) on listattuna 13 pörssissä, muun muassa: NYSE (MRNA), London (0A45.L), SIX (Zürich) (0QF.SW), XETRA (0QF.DE), Frankfurt (0QF.F), München (0QF.MU), Stuttgart (0QF.SG), Düsseldorf (0QF.DU).

Moderna Inc is a biotechnology company focused on the development and production of mRNA therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts, USA. The core divisions of Moderna Inc include research and development, production, and marketing of mRNA-based therapeutics and vaccines. In the field of research and development, Moderna Inc is working to discover and develop new therapies and vaccines for a variety of diseases. The company has a broad range of therapy areas such as immuno-oncology, infectious diseases, rare diseases, autoimmune diseases, and cardiovascular diseases. Moderna Inc's product line includes mRNA-based therapeutics and vaccines. The company has already conducted several clinical trials in various therapy areas, including cancer, heart attack, and influenza. The company has also developed and produced vaccines against COVID-19, which have already been approved by many countries and used by millions of people worldwide. Moderna Inc also operates a production facility in Massachusetts, USA. The company has a proven ability to rapidly and on a large scale produce mRNA-based products, enabling it to quickly respond to epidemics and pandemics, as was the case with the COVID-19 pandemic. Moderna Inc's business model is based on the commercialization of mRNA-based therapeutics and vaccines. The company leverages its advanced technology and state-of-the-art production processes to develop fast and effective solutions for fighting diseases. The company has also formed partnerships with other companies, government agencies, and universities around the world to share and expand its technology and expertise. Moderna Inc is a publicly traded company listed on the Nasdaq stock exchange in the USA. The company has a strong financial structure and has a wide range of investors and partners worldwide. Overall, Moderna Inc has an innovative and promising business model. By developing and producing mRNA-based products, the company is contributing to fighting a wide range of diseases and improving the well-being of people worldwide. With its strong market position and advanced technology, the company is well-positioned to continue growing and succeeding in the future.

odotettu liikevaihto Moderna on 2,10 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Moderna on −3,25 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Moderna:n hinta-voitto-suhde (P/E) on tällä hetkellä −23,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Moderna-osakkeen arvostusta.

Moderna:n hinta-myynti-suhde (P/S) on tällä hetkellä 36,47. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Moderna-osakkeen arvostuskennuslukuna.

Moderna:n Eulpool-laatuscore on 2/10.

Moderna:n ISIN on US60770K1079. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Moderna:n WKN on A2N9D9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Moderna:n ticker on MRNA. Tämä pörssinoteeraus käytetään Moderna-osakkeiden kauppaan pörssissä.